0001209191-21-008124.txt : 20210205 0001209191-21-008124.hdr.sgml : 20210205 20210205164958 ACCESSION NUMBER: 0001209191-21-008124 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210203 FILED AS OF DATE: 20210205 DATE AS OF CHANGE: 20210205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rosenberg Noah L. CENTRAL INDEX KEY: 0001579649 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 21596740 MAIL ADDRESS: STREET 1: C/O ESPERION THERAPEUTICS, INC. STREET 2: 46701 COMMERCE CENTER DRIVE CITY: PLYMOUTH STATE: MI ZIP: 48170 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262383102 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-03 0 0001438533 Travere Therapeutics, Inc. TVTX 0001579649 Rosenberg Noah L. C/O RETROPHIN, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 0 1 0 0 Chief Medical Officer Common Stock 2021-02-03 4 A 0 4500 0.00 A 48594 D (1) On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On February 3, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the DUPLEX study. /s/ Elizabeth E. Reed, Attorney-in-Fact 2021-02-05